<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="63612">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01702337</url>
  </required_header>
  <id_info>
    <org_study_id>114420</org_study_id>
    <nct_id>NCT01702337</nct_id>
  </id_info>
  <brief_title>Prevalence-based Health and Economic Model of the Bivalent Versus the Quadrivalent Human Papillomavirus (HPV) Vaccine</brief_title>
  <official_title>Additional Health and Economic Impact of the Bivalent Versus the Quadrivalent HPV Vaccine in Taiwan: Results of a Prevalence-based Model</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <authority>Taiwan: Food and Drug Administration, Department of Health</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compares the health and economic impact of the bivalent HPV vaccine (HPV-1) and
      the quadrivalent HPV vaccine (HPV-2).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study uses a prevalence-based model (by using efficacy data from each vaccine's
      respective trials and published cost data for Taiwan) which estimates the differences in
      lesions, genital warts, cervical cancer and costs from a healthcare payer's perspective
      prevented between HPV-1 and HPV-2 vaccines during one year (when all women are vaccinated).
      It also analyses costs from a societal perspective.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>N/A</study_design>
  <primary_outcome>
    <measure>Annual number of lesions prevented by each vaccine</measure>
    <time_frame>Over a one-year period</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Lesion related total cost averted by each vaccine</measure>
    <time_frame>Over a one-year period</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Additional costs averted by HPV-1 vaccine compared to HPV-2 vaccine</measure>
    <time_frame>Over a one-year period</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">1</enrollment>
  <condition>Human Papillomavirus Infection</condition>
  <arm_group>
    <arm_group_label>HPV-1 Group</arm_group_label>
    <description>Hypothetical group of women vaccinated with HPV-1 vaccine in Taiwan.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HPV-2 Group</arm_group_label>
    <description>Hypothetical group of women vaccinated with HPV-2 vaccine in Taiwan.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Prevalence-based model</intervention_name>
    <description>Static prevalence-based model to estimate vaccine effect over a one-year period at a steady state (when all women are fully vaccinated).</description>
    <arm_group_label>HPV-2 Group</arm_group_label>
    <arm_group_label>HPV-1 Group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Hypothetical group of women vaccinated with either HPV-1 or HPV-2 vaccines in Taiwan.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female subjects vaccinated with either HPV-1 or HPV-2 vaccines in Taiwan
             (hypothetical group).

        Exclusion Criteria:

          -  Not applicable.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <verification_date>October 2012</verification_date>
  <lastchanged_date>October 4, 2012</lastchanged_date>
  <firstreceived_date>September 27, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gardasil</keyword>
  <keyword>Prevalence-model</keyword>
  <keyword>Cervarix</keyword>
  <keyword>economic</keyword>
  <keyword>health</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Warts</mesh_term>
    <mesh_term>Papillomavirus Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
